Atopic Dermatitis: Therapeutic Challenges

Similar documents
What is atopic dermatitis?

Contact Dermatitis In Atopic Patients

Clinico Pathological Test SCPA605-Essential Pathology

What s Topical About Topicals?

RELEVANT DISCLOSURES. Consultant for Galderma Research grant from Ceragenix Investigator on Novartis study Research grant from Celgene

Children s Hospital Of Wisconsin

Skin Deep: Or is It? Practical Pearls from a Pediatric Dermatologist

UPDATES IN ATOPIC DERMATITIS

Atopic Eczema with detail on how to apply wet wraps

15 minute eczema consultation

Assessing the Current Treatment of Atopic Dermatitis: Unmet Needs

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Pharmacy Benefit Determination Policy

Biologic Therapies for Atopic Dermatitis and Beyond

Professor Rohan Ameratunga Clinical Immunologist and Allergist Auckland

The Itch That Rashes. Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah

8-year surveillance 2016 Atopic eczema in under 12s (2007) NICE guideline CG57

Hot topics in Pediatric Dermatology. Yvonne Chiu, MD

Conflicts of interest

RELEVANT DISCLOSURES ATOPIC DERMATITIS / ECZEMA MANAGING ECZEMA IN INFANTS AND CHILDREN

Learning Circle: Jan 26, 2011 Childhood Eczema

ATOPIC DERMATITIS: A BLUEPRINT FOR SUCCESS. Sierra Wolter MD, FAAD Pediatric Dermatology University of Arizona, College of Medicine

Eczema & Dermatitis Clinical features: Histopathological features: Classification:

Systemic treatment for moderate-to-severe atopic dermatitis? A systematic review and recommendation

Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Allergy Medications. Antihistamines. are very safe. Although usually taken as tablets, they may be prescribed as a liquid or syrup for young children

An Update on Topical Therapy for Atopic Dermatitis

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

Dermatology elective for yr. 5. Natta Rajatanavin, MD. Div. of dermatology Dep. Of Medicine, Ramathibodi Hospital Mahidol University 23 rd Feb 2015

Vulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough

Steroid use in managing your child s Atopic Eczema

Eucrisa. Eucrisa (crisaborole) Description

Managing and Minimizing Flare-ups in Atopic Dermatitis

Eucrisa. Eucrisa (crisaborole) Description

Diagnosis and Optimal Management of Atopic Dermatitis in the Pediatric Primary Care Setting

What to do when patch testing is negative?

Teledermatology Paediatric eczema. Dr Carolyn Charman Consultant Dermatologist Royal Devon and Exeter Hospital

Pharmacologic Treatment of Atopic Dermatitis

Atopic Dermatitis. Marcia Hogeling, MD Pediatric Dermatologist Phoenix Children s Hospital

5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema. Part 1. Keys to Adherence: Simplify regimen & Educate

ICHTHYOSIS. What are the aims of this leaflet?

ATOPIC DERMATITIS: PATHOPHYSIOLOGY AND PHARMACOLOGY OF MANAGEMENT PEGGY VERNON, RN, MA, C-PNP, DCNP, FAANP

Skin Manifestations of Allergy

INVESTIGATIONS & PROCEDURES IN PULMONOLOGY. Immunotherapy in Asthma Dr. Zia Hashim

ATOPIC ECZEMA. What are the aims of this leaflet?

See Important Reminder at the end of this policy for important regulatory and legal information.

New Medicine Report. Pimecrolimus. RED- Hospital only Date of Last Revision 6 th March 2003

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

Understanding. Atopic Dermatitis. National Jewish Health. An educational health series from

Note: AD stands for Atopic Dermatitis. Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.

Management of eczema in infants and children Assoc Prof David Orchard Director, Department of Dermatology Royal Children s Hospital

ATOPIC DERMATITIS: PATHOPHYSIOLOGY AND PHARMACOLOGY OF MANAGEMENT PEGGY VERNON, RN, MA, C-PNP, DCNP, FAANP

A Child with Eczema: A Parent s Guide

Dermatitis (inflammatory skin condition) Nonallergic. dermatitis. Non-atopic eczema (non- IgE mediated)

Faculty Information ECZEMA: THE ITCH THAT RASHES 2/13/2015. Disclosures and COI Resolution. Pharmacy Accreditation

Eczema. Most kids get itchy rashes at one time or another. But eczema can be a nuisance that may prompt scratching that makes the problem worse.

TREATMENT OF ALLERGIC SKIN DISEASES

RECLASSIFICATION SUBMISSION. EUMOVATE Eczema and Dermatitis Cream. (Clobetasone butyrate 0.05%) From Prescription Only Medicine

CHAPTER 1. Eczema Basics

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

Advisor. Atopic Dermatitis. The Asthma. enter. The Cycle of. Education and Research Fund

過敏病科中心. Allergy Centre. Eczema. Allergy Centre 過敏病科中心. Allergy Centre. For enquiries and appointments, please contact us at:

Overview. Atopic Dermatitis. Overview. 1. Genes and pathogenesis 2. Natural history and disease course 3. Comorbidities 4. Treatments 5.

Solving the Allergy Puzzle. Amy Haarstad DVM DACVD

Ailléirge Péidiatraiceach. Pediatric Allergy 3/9/2018. Disclosures & Conflicts Of Interest

Handout on Health: Atopic Dermatitis (A type of eczema)

Treatment with steroids and immunosuppressants

Using Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice)

New and emerging trends in the treatment of atopic dermatitis

The Medical Letter. on Drugs and Therapeutics

Is it allergy? Debbie Shipley

Associate Professor Rohan Ameratunga

Treating dermatomyositis

Prospective Trial Comparing Topical Steroid Application To Wet Versus Dry Skin In Children With Atopic Dermatitis

Approach to eczema. Hugo Van Bever Department of Pediatrics NUHS - Singapore

Anti-IgE: beyond asthma

Eosinophilic Esophagitis (EoE)

Atopic Dermatitis and Topical Antipsoriatics

Omalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication

Dupixent (dupilumab)

IMMUNODEFICIENCIES PRIMARY ALLERGIES PRIMARY IMMUNODEFICIENCIES AND ALLERGIES

Patching the Gaps in Our Diagnostic Knowledge. By Tyler Hooton MS3 UWSOM

Drug allergy and Skin Disorders. Timothy Craig, DO, FACOI Professor of Medicine and Pediatrics Distinguished Educator Penn State University, Hershey

An Everyday Guide to Eczema

See Important Reminder at the end of this policy for important regulatory and legal information.

Update on emollients

Lawrence F. Eichenfield, M.D.

WYNNIS L. TOM, MD: And I m Dr. Wynnis Tom. I m Associate Professor of Dermatology and Pediatrics at the University of California, San Diego.

Review Article Management of Patients with Atopic Dermatitis: The Role of Emollient Therapy

Dermatology Pearls and News Flash ACP Utah Chapter Scientific Meeting 2017

Update on systemic therapies and emerging treatments How do I choose a systemic agent?

Updates in Contact Dermatitis

Managing Atopic Derma00s: Itching the Night Away. Karol Timmons RN, MS, CPNP Boston Children s Hospital Atopic Derma00s Center

Allergy/Immunology Marshall University Pediatrics

Topical Immunomodulator Step Therapy Program

Overcoming Persistent Barriers to Effective Management of Atopic Dermatitis

Atopic Dermatitis Guidelines: What s New?

Clinical Review Report

Transcription:

Atopic Dermatitis: Therapeutic Challenges PDA August 14, 2009 Jon Hanifin OHSU, Portland Dominant Concepts in Atopic Dermatitis Allergy / Immunology Era: 1915-2006 The Epidermal Era: 2006---- Barrier dysfunction KC / immunocyte interactions Innate immunity

1/5/82: It s a barrier problem! Hydration protects! The Barrier Concept Outside-in Pathogenesis

Ichthyosis vulgaris F ilaggrin null mutations Palmer, Nature Genetics 2006 Hudson TJ: Nat Gen 38(4):399-400, 2006 Figure 1 Skin barrier function and allergic risk. An intact epithelial barrier (a) prevents allergens from reaching antigen-presenting cells (APCs) in subepithelial tissues. Damage to this barrier (b) allows allergens to penetrate into the subepidermal layer and interact with APCs, leading to allergic sensitization and, secondarily, to allergic manifestations in the host.

Treat the barrier--early The clinical presence of ichthyosis can predict patients/families with: Allergic respiratory disease A more severe AD phenotype Early onset AD Allergy

Atopic Dermatitis and Allergy AD is not an IgE-mediated disease AD is not an allergic skin disease AD is a skin disease which predisposes to allergies

Define Food Allergy An adverse health effect that results from stimulation of a specific immune response No immediate clinical reaction? Not allergy! Eczema ups & downs diagnosed as allergy are almost always wrong

Misdiagnosing Eczema as Food Allergy Positive allergy test only a test!!! Allergy is an immediate clinical reaction--by history or challenge Diet restriction--no challenge, no proof Skin care diverted to allergy search-- eczema continues

Allergy and AD: A more balanced perspective is needed for parents and pediatricians AD and ichthyosis promote IgE production. Allergic reactivity is secondary to barrier dysfunction. We now recognize the potential to modulate / prevent allergic diseases with barrier care.

AD in Teenagers Rebelling out is a way of life Non-compliance is assumed Magical thinking must be replaced by reality Systematic care The teen s lowest priority Negotiate to find room on a full schedule

AD Management Considerations in Teenagers Sideline parents to consulting role Calls and appts initiate with teen Parent in room only at start and end Offer counseling Lower the threshold for considering systemic therapy (e.g. CsA, MTX) Adult Onset AD Rare in temperate climates Can follow move from tropics Might signal Allergic contact dermatitis Lymphoma Always consider biopsy (JAAD 2005, 52: 579-82 BJD 2006, 155:557-60)

Adult-onset recalcitrant eczema: A possible marker for lymphoma or leukemia Callen, JP, et.al. JAAD 2000, 43:207-10

Hand Eczema & Eyelid Dermatitis ACD or AD? AD much more frequent cause Treat first; patch tests if recalcitrant Calcineurin inhibitors crucial for control of AD eyelid problems

Case Finding for Adult Onset AD Sensitive skin? Infant or early childhood eczema? Adult can t recall mild/mod disease Maybe only manifest in winter Parents needed for history?food allergy Mime the itch scratch antecubitals/popliteals

NACDG Patch Test tray negative

30 yo Asian/American man Flaring of chronic AD with lichenification, pigmentation and itch using only Cetaphil cr Similar presentation 3 yrs ago; responded well to topicals steroids and CI s Stopped all medications because of warnings Hesitant to restart Especially concerned about steroid near eyes Hates ointments

Discussion/Negotiation Why flaring? Winter?, out of meds??depressed Options Topicals safer than systemics Potent steroids needed for lichenified lesions No danger from short-term, aggressive use Evaluate each week phone or clinic Regimen Betamethasone ung (1#) b.i.d after 20 minute tub bath for 1 week Only 3-4 days on face, then TCI Call 1 wk plan taper to qd x 1 wk, then qod, then goal: twice weekly

Obstacles to Effective Management of AD Temerity (physician & patient) in using topical steroids Confusion and compliance issues Proper topical care diverted by allergy-seeking behavior

Common Glitches in Prescribing Topical Steroids Confusing when more than one steroid prescribed initially (triamcinolone 0.1% safe on face bid x 3d; then biw) Failing to hydrate before topical medication Dilution (mixing steroid + emollient or TCI) reduces drug effect Vehicle creams can t compete Size matters!!! Small tubes cause recurrent flares Impact of Topical Calcineurin Inhibitors Effective anti-inflammatory to follow corticosteroids Safe (hopefully long-term) maintenance for prolonged therapy More efficient management of AD patients: Increased optimism with good control Reduced concern about allergy Potential to reduce later allergy

Barrier Maintenance Devices: Atopiclair, Epiceram, MimyX For maintenance over co-existing skin cancer areas For steroid over-indulgers Recurrent infection sites For steroidophobics For the well-insured

Newer Topical Steroid Products Desonate 0.05% desonide in hydrocolloid gel * Verdeso--0.05% desonide foam * Olux-E 0.05%clobetasol in emollient foam Cutivate 0.05% fluticasone lotion Vanos--0.1% cream *These and fluticasone cream approved for infants as young as 3 months Unsupported Therapies used in AD Antihistamines Cromolyn Leukotriene inhibitors Allergy shots (aka immunotherapy ) Probiotics Borage/Evening Primrose oils Herbals Anti-IgE

Systemic Therapy of AD Cyclosporin A Antibiotics Gamma interferon Methotrexate* Azathioprene Mycophenolate mofetil* Systemic steroids IVIg* Leukotriene inhibitors** Antihistamines** Anti-IgE (Xolair)** Thalidomide* * No Randomized Clinical Trials ** RCT S show no benefit Biologic agents for AD!Will they be effective for AD?!Are they safe?!which might show efficacy?!interferon-gamma!omalizumab and rituximab